Abstract:Malignant melanoma is the most aggressive form of skin cancer. Standard treatment options include surgery, radiation therapy, systemic chemotherapy, targeted therapy, and immunotherapy. Combining these modalities often yields better responses. Surgery is suitable for localized cases, sometimes involving lymph node dissection and biopsy, to assess the spread of the disease. Radiation therapy may be sometimes used as a standalone treatment or following surgical excision. Systemic chemotherapy, while having low response rates, is utilized as part of combination treatments or when other methods fail. The development of resistance to systemic chemotherapies and associated side effects have prompted further research and clinical trials for novel approaches. In the case of advanced-stage melanoma, a comprehensive approach may be necessary, incorporating targeted therapies and immunotherapies that demonstrate significant antitumor activity. Targeted therapies, including inhibitors targeting BRAF, MEK, c-KIT, and NRAS, are designed to block the specific molecules responsible for tumor growth. These therapies show promise, particularly in patients with corresponding mutations. Combination therapy, including BRAF and MEK inhibitors, has been evidenced to improve progression-free survival; however, concerns about resistance and cutaneous toxicities highlight the need for close monitoring. Immunotherapies, leveraging tumor-infiltrating lymphocytes and CAR T cells, enhance immune responses. Lifileucel, an FDA-approved tumor-infiltrating lymphocyte therapy, has demonstrated improved response rates in advanced-stage melanoma. Ongoing trials continue to explore the efficacy of CAR T-cell therapy for advanced melanoma. Checkpoint inhibitors targeting CTLA-4 and PD-1 have enhanced outcomes. Emerging IL-2 therapies boost dendritic cells, enhancing anticancer immunity. Oncolytic virus therapy, approved for advanced melanoma, augments treatment efficacy in combination approaches. While immunotherapy has significantly advanced melanoma treatment, its success varies, prompting research into new drugs and factors influencing outcomes. This review provides insights into current melanoma treatments and recent therapeutic advances.

Intralesional and Infusional Updates for Metastatic Melanoma

Current status of intralesional agents in treatment of malignant melanoma

Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma

A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first‐line treatment for patients with melanoma in‐transit metastases

Therapeutic Treatment Options for In-Transit Metastases from Melanoma

Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver

Investigational Approaches for Treatment of Melanoma Patients Progressing After Standard of Care

Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma

Recent Advancements in Cell-Based Therapies in Melanoma

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions

Research progress of intralesional injection for advanced skin melanoma

Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma

A Review of Current and Pipeline Drugs for Treatment of Melanoma

Immunotherapy of Melanoma: a Critical Review of Current Concepts and Future Strategies

Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives

Immunotherapy of melanoma: a critical review of current concepts and future strategies.

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions

Melanoma—Modern Treatment for Metastatic Melanoma

Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma

Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients